CD274 and neuroendocrine neoplasm: Only a few studies in literature report patients treated with immunotherapy, mainly pretreated patients, showing a higher percentage of PD-L1 expression in comparison to other neuroendocrine tumors (especially SCLC) and a moderate efficacy of checkpoint inhibitors (19, 20).